IceCure Medical price target raised to $2.90 from $1.90 at Alliance Global Partners

Alliance Global Partners raised the firm’s price target on IceCure Medical to $2.90 from $1.90 and keeps a Buy rating on the shares. The firm is raising its valuation multiple by one turn and no longer discounting back by 15% due to the passage of time given what it views as “an imminent FDA clearance on the horizon.” The firm sees a “highly favorable risk-reward profile,” the analyst added.